Omeros (NASDAQ:OMER) Rating Increased to Buy at ValuEngine

Omeros (NASDAQ:OMER) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a report released on Thursday, ValuEngine reports.

A number of other equities research analysts also recently commented on OMER. Zacks Investment Research downgraded Omeros from a “hold” rating to a “sell” rating in a report on Wednesday, July 17th. Wedbush reiterated a “neutral” rating and issued a $18.00 price objective on shares of Omeros in a report on Monday, July 15th. HC Wainwright set a $35.00 price objective on Omeros and gave the company a “buy” rating in a report on Tuesday, May 28th. Cantor Fitzgerald started coverage on Omeros in a report on Monday, May 6th. They issued an “overweight” rating and a $26.00 price objective for the company. Finally, BidaskClub upgraded Omeros from a “sell” rating to a “hold” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Omeros presently has an average rating of “Hold” and an average price target of $25.80.

Shares of OMER stock traded up $0.07 on Thursday, reaching $15.32. 302,520 shares of the stock were exchanged, compared to its average volume of 399,532. The company has a market capitalization of $760.89 million, a PE ratio of -6.90 and a beta of 2.98. Omeros has a one year low of $10.30 and a one year high of $27.00. The firm’s 50 day moving average price is $15.49.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.04). The firm had revenue of $21.80 million during the quarter, compared to the consensus estimate of $23.18 million. The firm’s revenue was up 1271.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.62) EPS. On average, research analysts expect that Omeros will post -1.68 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. Aperio Group LLC bought a new stake in Omeros in the second quarter valued at about $49,000. Advisory Services Network LLC bought a new stake in Omeros in the first quarter valued at about $69,000. Legal & General Group Plc increased its holdings in Omeros by 12.7% in the fourth quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 945 shares during the last quarter. BNP Paribas Arbitrage SA grew its stake in Omeros by 16,167.2% in the first quarter. BNP Paribas Arbitrage SA now owns 9,923 shares of the biopharmaceutical company’s stock valued at $172,000 after acquiring an additional 9,862 shares during the period. Finally, Metropolitan Life Insurance Co. NY grew its stake in Omeros by 417.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 16,004 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 12,911 shares during the period. Institutional investors and hedge funds own 51.86% of the company’s stock.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: What does an equal weight rating mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.